Crossref

1. The Evaluation of Interferon Lambda 4 rs368234815 as a Predictor Factor in Treated Patients with Chronic Hepatitis C Genotype 1a Infection

- Shahram Jalilian

- Seyed Mahmoud Latifi

- Manoochehr Makvandi

- Ali Teimoori

- Azarakhsh Azaran

- Mehdi Parsanahad

- Gholamabas Kayedani

2. Treatment-emergent depression and anxiety between peginterferon alpha-2a versus alpha-2b plus ribavirin for chronic hepatitis C

- Liang-Jen Wang

- Shuo-Wei Chen

- Chih-Ken Chen

- Cho-Li Yen

- Jia-Jang Chang

- Tsung-Shih Lee

- Ching-Jung Liu

- Li-Wei Chen

- Rong-Nan Chien

3. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline

- Seyed Moayed Alavian

- Behzad Hajarizadeh

- Kamran Bagheri Lankarani

- Heidar Sharafi

- Nasser Ebrahimi Daryani

- Shahin Merat

- Minoo Mohraz

- Masoud Mardani

- Mohamad Reza Fattahi

- Hossein Poustchi

- Mehri Nikbin

- Mahmood Nabavi

- Peyman Adibi

- Masood Ziaee

- Bita Behnava

- Mohammad Saeid Rezaee-Zavareh

- Massimo Colombo

- Hatef Massoumi

- Abdul Rahman Bizri

- Bijan Eghtesad

- Majid Amiri

- Ali Namvar

- Khashayar Hesamizadeh

- Reza Malekzadeh

4. Psychiatric side effects of pegylated interferon‑α and ribavirin therapy in Iranian patients with chronic hepatitis C: A meta‑analysis

- Lotfollah Davoodi

- Babak Masoum

- Mahmood Moosazadeh

- Hamed Jafarpour

- Mohammad Haghshenas

- Tahoora Mousavi

5. Clinical correlations between chronic hepatitis C infection and decreasing bone mass density after treatment with interferon-alpha

- Vahid Babaei

- Masoud Ghorbani

- Nastaran Mohseni

- Hojjat Afraid

- Yassaman Saghaei

- Shahram Teimourian